Cargando…

Adenosine A(2A) receptor in schizophrenia: an in vivo brain PET imaging study

Adenosine A(2A) receptors are highly enriched in the basal ganglia system, a region that is functionally implicated in schizophrenia. Preclinical evidence suggests a cross-regulation between adenosine A(2A) and dopamine D(2) receptors in this region and that it is linked to the sensitization of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marques, Tiago Reis, Natesan, Sridhar, Rabiner, Eugenii A., Searle, Graham E., Gunn, Roger, Howes, Oliver D., Kapur, Shitij
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584985/ https://www.ncbi.nlm.nih.gov/pubmed/34175983 http://dx.doi.org/10.1007/s00213-021-05900-0

Ejemplares similares

O5.5. THE NEUROBIOLOGY OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: MULTI-MODAL PET AND FMRI FINDINGS
por: Howes, Oliver, et al.
Publicado: (2020)

Specific and non-specific binding of a tracer for the translocator-specific protein in schizophrenia: an [11C]-PBR28 blocking study
por: Marques, Tiago Reis, et al.
Publicado: (2021)

The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study
por: Onwordi, Ellis Chika, et al.
Publicado: (2021)

O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS
por: Chika Onwordi, Ellis, et al.
Publicado: (2020)

Reduced mu opioid receptor availability in schizophrenia revealed with [(11)C]-carfentanil positron emission tomographic Imaging
por: Ashok, Abhishekh H., et al.
Publicado: (2019)

The histamine system and cognitive function: An in vivo H3 receptor PET imaging study in healthy volunteers and patients with schizophrenia
por: Arumuham, Atheeshaan, et al.
Publicado: (2023)

Reward processing in schizophrenia and its relation to Mu opioid receptor availability and negative symptoms: A [(11)C]-carfentanil PET and fMRI study
por: Shatalina, Ekaterina, et al.
Publicado: (2023)

Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats
por: Onwordi, Ellis Chika, et al.
Publicado: (2020)

Identifying improved TSPO PET imaging probes through biomathematics: The impact of multiple TSPO binding sites in vivo
por: Guo, Qi, et al.
Publicado: (2012)

Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development
por: McCluskey, Stuart P., et al.
Publicado: (2019)

Acute acetate administration increases endogenous opioid levels in the human brain: A [(11)C]carfentanil molecular imaging study
por: Ashok, Abhishekh H, et al.
Publicado: (2021)

Patterns of Mitochondrial TSPO Binding in Cerebral Small Vessel Disease: An in vivo PET Study With Neuropathological Comparison
por: Wright, Paul, et al.
Publicado: (2020)

Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [(11)C]MP-10 PET rodent imaging study with ex vivo confirmation
por: Natesan, S, et al.
Publicado: (2014)

Molecular imaging as a guide for the treatment of central nervous system disorders
por: Kim, Euitae, et al.
Publicado: (2013)

Dissection of neuroinflammation in schizophrenia
por: Muratib, Fizah, et al.
Publicado: (2021)

Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [(11)C]PHNO PET
por: Rabiner, Eugenii A., et al.
Publicado: (2021)

The effects of AUT00206, a novel Kv3.1/3.2 potassium channel modulator, on task-based reward system activation: a test of mechanism in schizophrenia
por: Kaar, Stephen J., et al.
Publicado: (2022)

Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies
por: Marques, Tiago Reis, et al.
Publicado: (2019)

Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases
por: Wilson, Heather, et al.
Publicado: (2020)

Quantification of human brain PDE4 occupancy by GSK356278: A [(11)C](R)-rolipram PET study
por: van der Aart, Jasper, et al.
Publicado: (2017)

In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis
por: Borgan, Faith, et al.
Publicado: (2019)

Pre-frontal parvalbumin interneurons in schizophrenia: a meta-analysis of post-mortem studies
por: Kaar, Stephen J., et al.
Publicado: (2019)

The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study
por: Jauhar, Sameer, et al.
Publicado: (2019)

An evaluation of the brain distribution of [(11)C]GSK1034702, a muscarinic-1 (M(1)) positive allosteric modulator in the living human brain using positron emission tomography
por: Ridler, Khanum, et al.
Publicado: (2014)

Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures
por: Osimo, Emanuele Felice, et al.
Publicado: (2018)

Regulation of dopaminergic function: an [(18)F]-DOPA PET apomorphine challenge study in humans.
por: Jauhar, S, et al.
Publicado: (2017)

Correction: Regulation of dopaminergic function: an [(18)F]-DOPA PET apomorphine challenge study in humans
por: Jauhar, S., et al.
Publicado: (2018)

Correction: Regulation of dopaminergic function: An [(18)F]-DOPA PET apomorphine challenge study in humans
por: Jauhar, S, et al.
Publicado: (2019)

Brain volume in chronic ketamine users — relationship to sub-threshold psychotic symptoms and relevance to schizophrenia
por: Chesters, Robert A., et al.
Publicado: (2021)

Brain glucose metabolism in schizophrenia: a systematic review and meta-analysis of (18)FDG-PET studies in schizophrenia
por: Townsend, Leigh, et al.
Publicado: (2023)

Determinants of treatment response in first-episode psychosis: an (18)F-DOPA PET study
por: Jauhar, Sameer, et al.
Publicado: (2018)

The relationship between reward and punishment processing and the 5-HT(1A) receptor as shown by PET
por: Faulkner, Paul, et al.
Publicado: (2014)

Association between cannabinoid 1 receptor availability and glutamate levels in healthy controls and drug-free patients with first episode psychosis: a multi-modal PET and 1H-MRS study
por: Borgan, Faith, et al.
Publicado: (2020)

F180. CANNABINOID 1 RECEPTOR AVAILABILITY & MEMORY FUNCTION IN FIRST EPISODE PSYCHOSIS: A MULTI-MODAL PET-FMRI STUDY
por: Borgan, Faith, et al.
Publicado: (2018)

T45. THE EFFICACY AND HETEROGENEITY OF ANTIPSYCHOTIC RESPONSE IN SCHIZOPHRENIA: A META-ANALYSIS
por: McCutcheon, Rob, et al.
Publicado: (2020)

Comparison of four (11)C-labeled PET ligands to quantify translocator protein 18 kDa (TSPO) in human brain: (R)-PK11195, PBR28, DPA-713, and ER176—based on recent publications that measured specific-to-non-displaceable ratios
por: Fujita, Masahiro, et al.
Publicado: (2017)

Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications
por: Pillinger, Toby, et al.
Publicado: (2019)

First evaluation of PET-based human biodistribution and radiation dosimetry of (11)C-BU99008, a tracer for imaging the imidazoline(2) binding site
por: Venkataraman, Ashwin V., et al.
Publicado: (2018)

The neural and molecular basis of working memory function in psychosis: a multimodal PET-fMRI study
por: Borgan, Faith, et al.
Publicado: (2019)

Thermal Imaging Is a Noninvasive Alternative to PET/CT for Measurement of Brown Adipose Tissue Activity in Humans
por: Law, James, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h0rl1ll98rhnb3s9fm1g95eot2